Ochoa or Urofacial syndrome.

Indian Pediatr

Department of Pediatrics, Grant Medical College and Sir JJ Group of Hospitals, Byculla, Mumbai 400 008, India.

Published: May 2010

We report a 10 year old boy presenting with bilateral hydronephrosis and peculiar facial expression suggestive of Ochoa Syndrome or Urofacial syndrome. He had chronic renal failure which was managed conservatively.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13312-010-0067-5DOI Listing

Publication Analysis

Top Keywords

urofacial syndrome
8
ochoa urofacial
4
syndrome report
4
report year
4
year boy
4
boy presenting
4
presenting bilateral
4
bilateral hydronephrosis
4
hydronephrosis peculiar
4
peculiar facial
4

Similar Publications

Little attention was given to heparanase 2 (Hpa2) over the last two decades, possibly because it lacks a heparan sulfate (HS)-degrading activity typical of heparanase. Emerging results suggest, nonetheless, that Hpa2 plays a role in human pathologies, including cancer progression where it functions as a tumor suppressor. Here, we examined the role of Hpa2 in cervical carcinoma.

View Article and Find Full Text PDF

Genetic Contributions to Lower Urinary Tract Dysfunction.

Am J Med Genet A

January 2025

Division of Nephrology, Boston Children's Hospital, Harvard Medical School, Boston, United States.

Article Synopsis
  • * Non-neurogenic neurogenic bladder (NNNB) is diagnosed when a child shows urinary control issues without neurological problems, and there's growing evidence suggesting genetic causes for these symptoms, rather than just behavioral factors.
  • * In a study involving five children with NNNB or severe LUTD, researchers found two cases with genetic mutations—one in the HPSE2 gene and another in the ARL6 gene—which highlights the importance of considering genetic testing for affected children.
View Article and Find Full Text PDF

Urofacial syndrome or Ochoa syndrome (UFS or UFOS) is a rare disease characterized by inverted facial expression and bladder dysfunction that was described for the first time in Colombia. It is an autosomal recessive pathology with mutations in the HPSE2 and LRIG2 genes. However, 16% of patients do not have any mutations associated with the syndrome.

View Article and Find Full Text PDF

Human gene transfer ameliorates bladder pathophysiology in a mutant mouse model of urofacial syndrome.

Elife

July 2024

Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, United Kingdom.

Article Synopsis
  • Researchers studied early-onset urinary tract disorders like urofacial syndrome (UFS), which is caused by a mutation affecting bladder function and can lead to kidney failure.
  • Current treatments don't address the core issues of these disorders, prompting the exploration of a gene therapy approach using an adeno-associated viral (AAV9) vector to deliver the missing gene in neonatal mice.
  • The treatment successfully expressed the missing protein in the pelvic ganglia and improved bladder function, suggesting that AAV9 gene therapy may offer a potential cure for UFS and related neurogenic bladder issues.
View Article and Find Full Text PDF

HPSE2, the gene-encoding heparanase 2 (Hpa2), is mutated in urofacial syndrome (UFS), a rare autosomal recessive congenital disease attributed to peripheral neuropathy. Hpa2 lacks intrinsic heparan sulfate (HS)-degrading activity, the hallmark of heparanase (Hpa1), yet it exhibits a high affinity toward HS, thereby inhibiting Hpa1 enzymatic activity. Hpa2 regulates selected genes that promote normal differentiation, tissue homeostasis, and endoplasmic reticulum (ER) stress, resulting in antitumor, antiangiogenic, and anti-inflammatory effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!